If you've seen PMOS in the news recently and wondered whether it's a new condition, a replacement for PCOS, or something else entirely — you're not alone. This is one of the most significant shifts in women's hormonal health in decades, and the information circulating is patchy at best.
The short answer is yes: PMOS is PCOS, renamed. But the reasoning behind that change, and what it means practically for the millions of women already diagnosed or still seeking answers, is worth understanding properly.
This piece draws directly from the primary sources: the international consensus paper published in The Lancet on 12 May 2026, the Endocrine Society's formal statement, and NICE's first UK-specific draft guideline for PMOS, published 1 July 2026.
Quick Answer
PMOS (polyendocrine metabolic ovarian syndrome) is the new official name for what was previously called polycystic ovary syndrome (PCOS). The condition itself has not changed. Diagnostic criteria remain the same. Existing diagnoses remain valid. The name was changed because "polycystic ovary syndrome" was clinically inaccurate and had measurable consequences for diagnosis, care and understanding of the condition.
Where the New Name Came From
The rename wasn't a rebranding exercise. It was the result of a 14-year global process, culminating in a paper published in The Lancet on 12 May 2026, developed through iterative surveys and workshops involving more than 14,360 participants — patients and multidisciplinary health professionals from all world regions — alongside formal input from 56 leading academic, clinical and patient organisations, including the Endocrine Society, the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM).
According to the Endocrine Society's statement, the process concluded that the old name "reduced a complex, long-term hormonal or endocrine disorder to a misunderstanding about cysts and a focus on ovaries" — contributing to missed diagnoses and inadequate treatment.
The Lancet paper itself put it plainly: the term PCOS was "inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing."
What Each Word in PMOS Actually Means
The new name was chosen because each word does specific work that the old name failed to do.
Polyendocrine acknowledges that multiple interacting hormonal systems are involved — not just the ovaries, but insulin signalling, the hypothalamic-pituitary axis, adrenal androgens, and in some cases thyroid function. The condition has never been a single-hormone problem, and the name now reflects that.
Metabolic places insulin resistance and the associated cardiometabolic risks — including elevated risk of type 2 diabetes, dyslipidaemia and hypertension — at the centre of the condition rather than treating them as incidental features. Gold-standard clamp studies have found insulin resistance in approximately 75% of lean women and 95% of women with overweight who carry the diagnosis, with insulin sensitivity reduced by roughly 27% independent of BMI. This wasn't reflected in the old name at all.
Ovarian retains the ovarian involvement — irregular ovulation and follicular morphology — that remains a defining diagnostic feature, without implying that pathological cysts are the centre of the problem. Because they never were. The small follicles visible on ultrasound in PMOS are not the kind of cysts people ordinarily fear — they are small, developing follicles that have paused before ovulation, not fluid-filled cysts of the kind seen in ovarian cyst disease.
What Actually Changed — and What Didn't
This is the question that matters most for women currently living with the condition.
What has not changed:
- The condition itself — same biology, same mechanisms
- The diagnostic criteria — the Rotterdam criteria (2 of 3 required) remain the clinical standard
- Existing diagnoses — a PCOS diagnosis made before May 2026 is entirely valid and does not need to be re-obtained
- Prescriptions and treatment plans — all continue unchanged
- NHS entitlements and insurance coverage — unaffected during the transition
- ICD-10 code E28.2 — remains in use during the transition period
What has changed:
- The official name, now used in clinical and research literature
- The conceptual framework — from an ovary-centred to a multisystem endocrine-metabolic condition
- The expected direction of clinical guidelines, with broader recognition of cardiometabolic and psychological dimensions alongside reproductive ones
The Rotterdam Criteria: How PMOS Is Diagnosed
Diagnosis of PMOS requires meeting 2 out of 3 Rotterdam criteria, after excluding other conditions that can cause similar symptoms — including thyroid disease, congenital adrenal hyperplasia, hyperprolactinaemia and androgen-secreting tumours.
The three criteria are:
- Irregular or absent menstrual cycles — oligo-ovulation or anovulation
- Clinical or biochemical signs of elevated androgens — this includes acne, hirsutism or scalp hair thinning on examination, or elevated androgen levels on a blood test
- Polycystic ovarian morphology — visible on ultrasound or indicated by an elevated anti-Müllerian hormone (AMH) blood test
Meeting any two of these three, once other causes have been ruled out, is sufficient for diagnosis. You do not need all three. And crucially, you do not need visible "cysts" on an ovarian ultrasound — the AMH blood test is now an accepted alternative to ultrasound for the third criterion, which is clinically significant for women who find pelvic ultrasound difficult or inaccessible.
Why the Old Name Caused Real Harm
The consequences of an inaccurate name weren't abstract. In the Lancet consensus process, 86% of patients and 71% of clinicians supported the name change, citing stigma, confusion and fragmented care as the primary drivers.
The damage the old name caused played out in several ways. Women with regular periods who also had elevated androgens and metabolic symptoms were frequently told they couldn't have PCOS — because the assumption was that cycles had to be irregular. Women who had ultrasounds showing no visible cysts were similarly dismissed, even when they met the other criteria on blood testing. Lean women faced diagnostic delays of 2 to 3 years on average because the assumption that the condition mainly affected women with overweight was baked into how clinicians thought about it.
Beyond diagnosis, the fertility-centric framing of the old name meant women were often told the condition "only mattered if they wanted to get pregnant." The cardiometabolic picture — the elevated long-term risk of type 2 diabetes, cardiovascular disease and metabolic dysfunction that accompanies PMOS regardless of reproductive goals — was systematically under-communicated.
What This Means in the UK Right Now
The UK is in transition. NICE published the first UK-specific draft guideline for PMOS on 1 July 2026 — the first national guidance for NHS treatment of the condition — covering management of PMOS alongside associated features including acne, hirsutism and obstructive sleep apnoea. The final guideline is expected in December 2026.
As of now, the NHS condition page still uses PCOS terminology. NHS digital content typically follows NICE guidance updates rather than leading them, and the page is expected to transition to PMOS language once revised NICE documentation is published — most likely in early-to-mid 2027. During this period, both terms will appear in NHS documents as the older terminology is phased out.
The transition period runs until approximately 2028 to 2029, when the ICD-11 update is expected to formally incorporate PMOS coding. Healthcare systems are planning to map existing PCOS diagnoses to PMOS in electronic health records during this window — no action is required from patients.
PMOS, Perimenopause and the Overlap Many Women Are Navigating
One dimension of PMOS that deserves more attention than it receives is what happens for women who reach their late 30s and 40s still managing the condition. PMOS doesn't resolve at menopause — the cardiometabolic and hormonal features evolve rather than disappear, and the overlap with perimenopausal oestrogen decline adds a second layer of hormonal complexity that most clinical content treats as entirely separate.
The inflammatory component of PMOS — the chronic low-grade inflammatory state associated with insulin resistance and androgen excess — can compound with the collagen loss driven by falling oestrogen. Both processes independently accelerate the breakdown of connective tissue, which is part of why women navigating PMOS into their 40s often report skin, joint and hair changes that general ageing frameworks don't fully explain. See Can Collagen Help with PCOS Symptoms? for the evidence on connective tissue and the PMOS-perimenopause overlap specifically.
This overlap is significant enough that we've dedicated a full pillar to it. For a deeper look at how PMOS (PCOS) and perimenopause interact — including symptom-by-symptom comparisons, weight, sleep, brain fog and fatigue — start with PCOS and Perimenopause: Can You Have Both at the Same Time?, our cornerstone guide to the overlap.
The broader point is that the new PMOS framework — by explicitly centring the metabolic and multi-system nature of the condition — should make it easier, not harder, for women in this overlap zone to have their full picture recognised rather than being told one condition is a reproductive issue and the other is just ageing.
A Note on Supplements and PMOS
Nothing in the name change alters the evidence base for nutritional support in PMOS. The same caveats apply as before: supplements are not a treatment for the condition and don't address its hormonal or metabolic root causes. What research does support is a role for targeted nutritional approaches in supporting the connective tissue, skin and inflammatory dimensions of a condition that affects far more than the ovaries.
For women managing PMOS who are also concerned about skin and connective tissue health — particularly those in the perimenopause transition — the halal certification of any supplement they use may also be relevant. Most bovine collagen on the UK market is not halal-certified, which matters for a condition with high prevalence in British Muslim and South Asian communities. See Best Collagen for Perimenopause in the UK for what to look for.
Frequently Asked Questions
Is PMOS the same as PCOS?
Yes. PMOS (polyendocrine metabolic ovarian syndrome) is the new official name for what was previously called polycystic ovary syndrome (PCOS). The condition is identical — only the name has changed, following a global consensus process published in The Lancet in May 2026. Diagnostic criteria, treatments and existing diagnoses all remain valid.
Does my existing PCOS diagnosis still count?
Yes, entirely. A PCOS diagnosis made before May 2026 is valid under the PMOS framework. You do not need to be re-diagnosed, re-tested or re-referred. Your medical history, prescriptions and NHS entitlements are unaffected. During the 2026 to 2028 transition period, healthcare systems are updating records to reflect the new terminology administratively — no action is required from patients.
Why was PCOS renamed PMOS?
The old name was clinically inaccurate. "Polycystic ovary syndrome" implied the condition was defined by pathological ovarian cysts — which it isn't. The small follicles visible on ultrasound are not the kind of cysts people fear, and around 30% of women diagnosed don't have visible follicular changes at all. More significantly, the cyst-centric name obscured the condition's endocrine and metabolic features — including insulin resistance, which affects the majority of those diagnosed — and contributed to delayed diagnosis, fragmented care and stigma over decades.
What does PMOS stand for?
Polyendocrine metabolic ovarian syndrome. Each word reflects a dimension of the condition: polyendocrine acknowledges multiple interacting hormonal systems; metabolic places insulin resistance and cardiometabolic risk at the centre; ovarian retains the ovarian involvement without implying pathological cysts are the defining feature.
Has the NHS updated its guidance to reflect PMOS?
NICE published the first UK-specific draft guideline for PMOS on 1 July 2026, with the final guideline expected in December 2026. The NHS condition page still uses PCOS terminology as of August 2026 and is expected to transition to PMOS language once the revised NICE documentation is published, likely in early-to-mid 2027. Both terms will appear in NHS documents during the transition period.
Do I need to tell my GP about the name change?
Not urgently. Your GP will be aware of or will become aware of the change through clinical updates. If you have an upcoming appointment and want to discuss what the new framework means for your care — particularly if the metabolic or cardiometabolic dimensions of PMOS haven't been addressed in your previous consultations — that is a reasonable and worthwhile conversation to have.
Does PMOS affect diagnosis for women who don't have visible ovarian cysts?
The PMOS framework should improve this situation over time. The Rotterdam criteria — unchanged — already allow diagnosis without visible follicular changes on ultrasound, since only 2 of 3 criteria are required and an elevated AMH blood test is an accepted alternative to ultrasound for the third criterion. The shift away from the "polycystic" framing should reduce the frequency with which women are dismissed because their ultrasound doesn't show what the old name implied was central to the diagnosis.
Key Takeaways
- PMOS is the same condition as PCOS — renamed on 12 May 2026 following a 14-year global consensus process published in The Lancet, endorsed by over 50 organisations including the Endocrine Society and ASRM.
- The condition, diagnosis, treatment and NHS entitlements are all unchanged. Existing diagnoses remain valid.
- The name changed because "polycystic ovary syndrome" was inaccurate — ovarian cysts are not the defining feature, and the old name obscured the condition's endocrine, metabolic and systemic dimensions for decades.
- NICE published the first UK-specific PMOS draft guideline on 1 July 2026, with final guidance expected December 2026. NHS terminology is expected to update in early-to-mid 2027.
- The new name should support earlier, more accurate diagnosis — particularly for lean women, women without visible follicular changes, and women whose metabolic picture has historically been under-addressed.
About Reem Supplements
Reem Supplements is a UK-based wellness brand specialising in liquid collagen supplements formulated for women experiencing hormonal changes, including PMOS (formerly PCOS) and perimenopause. Every batch is halal-certified — because many of the women navigating these hormonal transitions have had to choose between efficacy and their values for too long.
If you're managing PMOS and want to understand the connective tissue and skin picture in more depth, the PMOS and Collagen guide covers the evidence on inflammation, collagen breakdown and what may help. For women navigating both PMOS and perimenopause, Does Collagen Help During Perimenopause? addresses the overlapping hormonal picture directly, and our full PCOS and Perimenopause pillar covers the overlap symptom by symptom.